Tivozanib – Potent Selective VEGFR Tyrosine Kinase Inhibitor

Tivozanib is an oral, potent, and highly selective vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3 tyrosine kinase inhibitor. The drug was developed for the targeted therapy of advanced stages of oncological diseases, specifically advanced renal cell carcinoma (RCC) in adult patients. The primary mechanism of action of tivozanib involves blocking the autophosphorylation of VEGFR receptors, which leads to powerful suppression of angiogenesis signaling pathways. This effectively halts endothelial cell proliferation, prevents the formation of new blood vessels within the tumor, deprives the neoplasm of essential nutrients and oxygen, thereby slowing down tumor progression.

The uniqueness of tivozanib lies in its unprecedentedly high selectivity for all three VEGFR receptor types with minimal activity against off-target kinases (such as c-Kit, PDGFR, or FLT3). This property favorably distinguishes it from previous generations of multikinase inhibitors, as it allows for deep therapeutic suppression of angiogenesis at a significantly lower level of systemic toxicity and with better treatment tolerability. The drug possesses a long half-life (approximately 4–5 days), ensuring a stable concentration of the active substance in blood plasma throughout the entire therapeutic cycle. Tivozanib is rapidly and almost completely absorbed in the gastrointestinal tract and is metabolized predominantly in the liver with the involvement of cytochrome P450 system isoenzymes.

The drug is administered orally. Treatment is given in repeating cycles and requires regular monitoring of blood pressure and liver function throughout the entire course of therapy.

Wikipedia page
Tivozanib

Indications

Tivozanib is indicated for the treatment of adult patients with the following oncological conditions:

  • Renal Cell Carcinoma (RCC): first-line therapy for patients with advanced, metastatic, or recurrent clear cell renal cell carcinoma.
  • Refractory RCC: treatment of patients with progressive renal cell carcinoma following the failure of two or more prior systemic therapies (including immune checkpoint inhibitors or other TKIs).

Dosage and administration

The tivozanib dosing regimen is based on a cyclic schedule to optimize efficacy and manage patient tolerability.

  • Standard Dose: the recommended therapeutic dose is 1.34 mg (equivalent to 1.5 mg of tivozanib hydrochloride) taken orally once daily.
  • Cycle Schedule: the drug is taken daily for 21 days (3 weeks), followed by a 7-day rest period (1 week) without treatment. A full cycle constitutes 28 days.
  • Administration Method: capsules are swallowed whole with a glass of water at approximately the same time each day, with or without food. Do not open or chew the capsules.
  • Missed Dose: if a dose is missed, the patient should take the next dose the following day at the regularly scheduled time. Do not take a double dose to make up for a missed one.
  • Dose Modification: in case of severe adverse reactions (Grade 3 or 4 toxicities), the dose may be temporarily reduced to 0.89 mg daily, or treatment may be withheld until the condition stabilizes.

The use of tivozanib is restricted by strict clinical limitations and is contraindicated in the following conditions:

  • Hypersensitivity: known allergy or individual hypersensitivity to tivozanib or any of the inactive excipients of the drug.
  • Hepatic Impairment: severe hepatic impairment (Child-Pugh Class C), as the safety of use has not been evaluated in this population.
  • Renal Impairment: severe end-stage renal disease or patients undergoing hemodialysis.
  • Pregnancy and Lactation: the drug carries significant teratogenic and embryotoxic risks. Breastfeeding during treatment and for at least one month after the final dose is strictly prohibited.
  • Drug Interactions: concomitant use with strong CYP3A4 inducers (e.g., rifampin, St. John's wort) is contraindicated, as they significantly reduce the efficacy of tivozanib.

The side effects of tivozanib are predominantly driven by the specific inhibition of VEGFR pathways and the disruption of angiogenesis:

  • Cardiovascular System: arterial hypertension (the most frequent complication requiring antihypertensive therapy), and less commonly, thromboembolism, myocardial infarction, or stroke.
  • Respiratory System: dysphonia (hoarseness or voice alteration caused by effects on the laryngeal nerves), cough, dyspnea, and epistaxis (nosebleeds).
  • Digestive Tract: diarrhea, nausea, vomiting, stomatitis (inflammation of the oral mucosa), and significant decreased appetite leading to weight loss.
  • Integumentary System: palmar-plantar erythrodysesthesia syndrome (hand-foot syndrome), dry skin, skin rash, or alopecia.
  • General Symptoms and Laboratory Values: pronounced asthenia (weakness), fatigue, hypothyroidism, as well as elevated liver transaminases (ALT, AST).

Frequently Asked Questions

Tivozanib is a next-generation oral tyrosine kinase inhibitor that selectively blocks all three vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3). Its primary advantage lies in its exceptional selectivity: it potently targets angiogenesis (the formation of new blood vessels that feed the tumor) while minimally inhibiting off-target kinases. This high selectivity allows for robust anti-tumor efficacy with a more favorable off-target toxicity profile.
Tivozanib is indicated for the treatment of adult patients with relapsed or refractory advanced (metastatic) renal cell carcinoma (RCC). It is typically prescribed for patients who have received two or more prior systemic therapies, including other VEGFR inhibitors or immunotherapy, and whose disease has code-progressed.
Tivozanib is administered in a cyclic treatment regimen: capsules are taken once daily for 21 days (3 weeks), followed by a 7-day break (1 week) without the drug. This establishes a complete 4-week (28-day) cycle. The capsules should be taken at a fixed time each day, with or without food, and must be swallowed strictly whole with water.
Hypertension (high blood pressure) is one of the most common and anticipated class-effects of tivozanib, resulting from VEGFR pathway inhibition. Blood pressure must be well-controlled prior to initiating therapy and monitored weekly thereafter, particularly during the first two cycles. If a significant increase occurs, anti-hypertensive therapy will be initiated or adjusted, and in severe cases, tivozanib may be temporarily withheld.
Beyond hypertension, common adverse events include dysphonia (hoarseness or voice changes), fatigue, diarrhea, and palmar-plantar erythrodysesthesia (hand-foot syndrome, presenting as redness and pain on the palms and soles). Immediate medical attention is required if symptoms of severe bleeding, intense chest pain, sudden shortness of breath, or thromboembolic events occur.

List of medicines by active substance

-9%
Tivoxen
View
Everest

Tivoxen

Tivozanib
1.34 mg 21 capsule
9387₴ 10281₴
✅ All products loaded (1)
Unifarm

Unifarm app

Safari → Share → Add to Home Screen Firefox: menu ⋮ → Install or Add to Home screen. If missing, open the site in Chrome. Chrome: menu ⋮ → Install app or Add to Home screen.

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00